The cancer immunotherapy developer has closed a $23.6m round featuring 3SBio Group and Eisai, both of which have signed collaboration agreements with it in recent months.

Optum Ventures and Heritage Provider Network reinvested as the healthcare expertise platform increased its overall funding to $40m with a series C round led by Deerfield Managment.

The ultrasound surgery system developer is targeting $150m at a $1.3bn post-money valuation, with Koch Disruptive Technologies supplying $100m.

Phoenix Group and Migdal have supplied capital for Arkin Bio-Ventures II, which investment firm Arkin Holdings will use to invest in 10 to 12 drug developers.

The vehicle will back early-stage life sciences proposals from Utrecht province with support from both UMC Utrecht and Utrecht University.

The Pharmaron-backed cancer therapy developer is targeting $100m in an initial public offering preceded by $162m in funding.

Novartis and Harel are among the investors set to exit the cancer therapy developer, which also counts Bristol-Myers Squibb as a shareholder.

Imperial College London has opened a new funding stream for its early-stage research with the launch of its Parkwalk Advisors-managed Innovation Fund.

The Qualcomm-backed musculoskeletal assessment software developer boosted its overall funding to $26m with a round led by GSR Ventures.

AIA, Tencent, Fosun, NWS Holdings and Tyan Home could exit the medical booking platform in an initial public offering valuing it at more than $10bn.